… In the present review, we summarized the current preclinical and clinical evidence of PEA
as a possible therapeutic agent in Alzheimer’s disease. The possible PEA neuroprotective …

… activities of systemic administration of PEA in adult male rats … the effects induced by PEA, we
co-administered PEA with the … : novel therapeutic strategies in Alzheimer's disease? Trends …

… Along this line palmitoylethanolamide (PEA) has attracted much attention … of PEA in rat
neuronal cultures and organotypic hippocampal slices challenged with Aβ, and treated with PEA …

… Considering the anti-inflammatory properties of PEA, and the existence of a PEA/PPAR-α
signaling at CNS level, we hypothesized that PEA may exert neuroprotective effect in an …

… palmitoylethanolamide (PEA) demonstrates exceptional potential as a novel treatment for
AD. We have previously demonstrated PEA … the effects of chronic PEA administration on the …

… an important role in neuroinflammatory disorders and in AD … compound such as
palmitoylethanolamide (PEA) and the well … in Alzheimer's disease. Ann Neurol 1997; 41(1): 17-24. …

… in the FC at an early stage of the disease. Moreover, we demonstrate for the first time that
acute PEA in vitro, as well as chronic um-PEA in vivo, may counteract such phenomenon, …

… Alzheimer’s disease (AD) are lacking. This study was designed to investigate the beneficial
effect of PEA … In addition, the ability of PEA in modulating the activation of enteric glial cells (…

… Among AEs, palmitoylethanolamide (PEA) is … of PEA have been mainly related to the
reduction of neuronal firing and to control of inflammation. Growing evidence suggest that PEA may …

… N-palmitoylethanolamide (PEA) is a lipid mediator belonging to the class of the N-acylethanolamine.
Products containing PEA, also in ultramicronized formulation (um-PEA), … that PEA, …